You are viewing Asia Pacific


Driving Intestinal Resilience

ENTEROSURE™ is a novel active microbial solution developed through many years of intense research. It drives the intestinal resilience of animals by directly inhibiting and managing the growth of specific pathogenic bacteria and promoting, restoring and maintaining a healthy microbiome. In this way, ENTEROSURE™ addresses intestinal health challenges, improves animal productivity, and helps animal producers produce profitable, efficient, and sustainable protein to meet the industry’s demand. 



  • ENTEROSURE™ is for animal production professionals who want to manage intestinal health challenges such as pathogenic bacterial outbreaks and dysbacteriosis and improve animal productivity.
  • ENTEROSURE™ provides a proprietary blend of probiotic Bacillus strains that directly inhibits the growth of pathogenic bacteria such as Clostridium perfringens and E. coli.
  • ENTEROSURE™ manages the prevalence of other Enterobacteriaceae and promotes, restores and maintains a healthy microbiome through the production of antimicrobial metabolites and quorum quenching molecules.
  • ENTEROSURE™ supports Antibiotic Growth Promoters (AGPs) reduction and removal programs.


ENTEROSURE driving intestinal resilience


Kemin Industries launches new probiotic solution, ENTEROSURE™

Kemin Industries has launched ENTEROSURE™ to control the growth of pathogenic bacteria in poultry and livestock. Kemin unveiled its latest intestinal health product at a global launch event in Dubai. The company’s newest probiotic solution promotes a healthy microbiome, drives intestinal resilience, manages gut health challenges and improves animal productivity.

Enteric disease challenges are an ever-present pressure on livestock and poultry producers, who are already facing significant performance and economic impact from the global trend toward reduced antimicrobial use and the rising cost of raw materials. These challenges require an effective and comprehensive solution that helps drive intestinal resilience to prevent disease before it develops – all while safeguarding animal health, welfare, growth and performance.  

“Leveraging the pioneering research that launched CLOSTAT™, our novel solution addresses the changing needs of animal producers,” said G.S. Ramesh, Worldwide Group President – Animal Nutrition and Health, Kemin Industries. “ENTEROSURE™, through its proprietary blend of probiotic Bacillus strains, expands on the scientifically proven efficacy of CLOSTAT™’s Bacillus subtilis PB6 against Clostridium perfringens by also managing the growth of Escherichia coli and other Enterobacteriaceae, such as Salmonella.”

Intestinal resilience is a crucial factor in producers’ hierarchy of needs for their animals; up to 80 percent of antimicrobial use is intended to achieve resilience in the gastrointestinal system, a vital component in animal production. Kemin continues to drive innovation through its probiotic research program to support intestinal health management.

The company undertook a multiyear, global project to discover advanced solutions to enhance intestinal resilience while maintaining a robust program to improve feed conversion and weight gain and combat pathogens that contribute to dysbiosis, diarrhea, wet litter issues, foot-pad lesions and mortality.



Poultry producers’ hierarchy of needs

World poultry meat production soared from 9 MMT to 132 MMT in the last 50 years and is still estimated to grow. This growth in poultry production can be more efficient and sustainable in terms of economic, environmental and people’s needs.

Intestinal resilience is one of the most crucial factors within the hierarchy of needs, as up to 80% of dietary antimicrobial inputs go through the gastrointestinal system. Therefore, achieving intestinal resilience is a vital step in poultry production.

ENTEROSURE  Poultry producers’ hierarchy of needs

Persistent challenges to enteric health

Poultry producers face significant performance and economic impacts due to the prevalent nature of enteric pathogens as well as multifaceted nonpathogenic factors. In addition, there is a disparity between the current antimicrobial products and their expected performance. These challenges call for an effective and comprehensive solution to cater to the unmet needs of the poultry producers. 

ENTEROSURE Persistent challenges to enteric health



Gram-positive enteric pathogen Gram-negative enteric pathogen Performance and ROI
“A stand-alone solution” for Clostridium perfringens induced enteritis management.  Leverages existing enteric E. coli and Salmonella spp. management. Delivers a minimum of 4 points FCR and 50 g body weight, with 4 times the minimum economic return on investment.


Mode of action

ENTEROSURE™ is a proprietary blend of probiotic Bacillus strains that secretes antimicrobial metabolites and quorum quenching molecules to directly inhibit and manage the growth of specific pathogenic bacteria and promote, restore and maintain a healthy microbiome, enabling the product to manage intestinal health challenges and improve animal productivity.

ENTEROSURE Mode of Action



Let's Work Together! Contact Us: Contact Us